Trial Profile
Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Carboplatin; Dexamethasone; Gemcitabine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms GHG-GCD
- 01 Jan 2024 Status has been changed to completed.
- 01 Jan 2024 Results of efficacy and safety of salvage chemotherapy with gemcitabine, carboplatin, dexamethasone, and rituximab , published in the Hematological Oncology
- 23 Dec 2014 New trial record